Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 11/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6000448 | 0.89 | HTR2A (0.37) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Formic Acid SCHEMBL6000411 | 0.87 | PARP1 (0.38) | SLC6A4KCNH2HTR2AHTR2CHTR1A | |
| SCHEMBL6000410 | 0.81 | HTR2A (0.39) | SLC6A4KCNH2HTR2AHTR2CHTR1A | |
| SCHEMBL5998739 | 0.77 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Formic Acid SCHEMBL6000415 | 0.77 | SLC6A4 (0.48) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Formic Acid SCHEMBL6000453 | 0.77 | HTR2A (0.37) | SLC6A4HTR2AHTR2CHTR1APARP1 | |
| SCHEMBL6000301 | 0.73 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5500697 | 0.72 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000452 | 0.71 | HTR2A (0.41) | SLC6A4HTR2AHTR2CHTR1A | |
| SCHEMBL5501635 | 0.71 | SLC6A4 (0.58) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885KCNH2 2331/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.